N/A
Completed N=21,340
A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
Source: ClinicalTrials.gov NCT06418529 ↗Enrolled (actual)
21,340
Serious AEs
—
Results posted
Jul 2025
Primary outcomePrimary: Incidence Rate of Low Disease Activity (LDA) or Remission Based on Clinical Disease Activity Index (CDAI) at 6-Months Follow-up: Tofacitinib vs. TNFi — 426.8; 471.9 Events per 1000 person years
Summary
The purpose of this study is to learn how different types of medicines may improve disease activity in people with rheumatoid arthritis (RA). RA is a kind of joint disease that causes pain and swelling.
The study will look at data from a large, US-based group of RA patients who have taken the below medicines:
* Tofacitinib
* Abatacept
* Tocilizumab or sarilumab
The study will compare clinical disease activity scores of patients on the different medicines taken. The study will also decide whether some patient traits or disease factors play a role in how medicines may improve disease activity.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence Rate of Low Disease Activity (LDA) or Remission Based on Clinical Disease Activity Index (CDAI) at 6-Months Follow-up: Tofacitinib vs. TNFi |
426.8; 471.9 | — |
| PRIMARY Incidence Rate of LDA or Remission Based on CDAI at 12-Months Follow-up: Tofacitinib vs. TNFi |
185.5; 200.4 | — |
| PRIMARY Incidence Rate of LDA or Remission Based on CDAI at 6-Months Follow-up: Tofacitinib vs. Abatacept |
421.1; 486.6 | — |
| PRIMARY Incidence Rate of LDA or Remission Based on CDAI at 12-Months Follow-up: Tofacitinib vs. Abatacept |
185.2; 203.1 | — |
| PRIMARY Incidence Rate of LDA or Remission Based on CDAI at 6-Months Follow-up: Tofacitinib vs. IL-6 |
401.7; 436.3 | — |
| PRIMARY Incident Rate of Low Disease Activity or Remission Based on CDAI at Month 12: Tofacitinib vs. IL-6, IPTW |
177.7; 181.7 | — |
Eligibility Criteria
Inclusion Criteria
- Age ≥18 years on the cohort entry date.
- Diagnosed with rheumatoid arthritis (RA) at any time prior to cohort entry date:
- At least two RA diagnosis codes at least 30 days apart, each coming from an encounter with a rheumatologist;
- At least one inpatient visit with a RA diagnosis code;
- At least two outpatient records with a RA diagnosis code at least 30 days apart and within a year, regardless of physician specialty; or
- At least one outpatient record with an RA diagnosis and a prescription or fill for a disease modifying anti-rheumatic drug (DMARD) from a specified list and does not have any of the non-RA conditions for which those drugs may also be prescribed.
- Initiation of specified biologic or targeted synthetic molecule DMARDs of interest for treatment of RA (ie, tofacitinib, etanercept, adalimumab, certolizumab, golimumab, infliximab, abatacept, tocilizumab, or sarilumab).
- At least 180 days of baseline data available prior to and including the cohort entry date.
- At least one Clinical Disease Activity Index (CDAI) score in 45 days prior to and including the cohort entry date (baseline).
Exclusion Criteria
- Patients diagnosed with concomitant indications for tofacitinib [psoriatic arthritis (PsA), UC, and polyarticular course juvenile idiopathic arthritis (pcJIA)] at any time prior to cohort entry date, determined by at least two (2) diagnosis codes at least 30 days apart and prior to baseline.
- Patients with >1 b/tsDMARD (ie, tofacitinib, etanercept, adalimumab, certolizumab, golimumab, infliximab, abatacept tocilizumab, or sarilumab) prescribed on index date.
Data sourced from ClinicalTrials.gov (NCT06418529). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.